NCT02546752View on ClinicalTrials.gov

Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

1,306

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Human Papilloma Virus Infection Type 11Human Papilloma Virus Infection Type 16Human Papilloma Virus Infection Type 18Human Papilloma Virus Infection Type 6Cervical Cancer
Interventions
OTHER

THEO

THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.

Trial Locations (5)

46202

Eskenazi Health Outpatient Care Center, Indianapolis

46208

Eskenazi Health Center Blackburn, Indianapolis

46226

Eskenazi Health Center Forest Manor, Indianapolis

46254

Eskenazi Health West 38th Street, Indianapolis

46268

Eskenazi Health Pecar, Indianapolis

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Regenstrief Institute, Inc.

OTHER

NCT02546752 - Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine | Biotech Hunter | Biotech Hunter